<DOC>
	<DOCNO>NCT01634373</DOCNO>
	<brief_summary>Objective : Primary objective study Steady-state bioequivalence Torrent 's Quetiapine Fumarate Tablets 300 mg. Study Design : Randomized , Two-Way , Crossover , multiple Dose , Open-Label</brief_summary>
	<brief_title>Steady State Bioequivalence Study Torrent Pharmaceuticals Ltd 's Bioequivalence Study Torrent Pharmaceuticals Ltd 's Quetiapine Tablets</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Sex : Male female Age : 2565 year Patients receive stable daily dose quetiapine 300 mg every 12 hourly atlist one month Patient willing adhere protocol requirement Clinically relevant abnormality result laboratory screening evaluation . Clinically significant abnormal ECG . Significant orthostatic hypotension ( i.e. , drop systolic blood pressure 30 mm Hg and/or drop diastolic blood pressure 20 mm Hg standing ) Concurrent use antihypertensive medication medication might predispose orthostatic hypotension . History allergic reaction quetiapine chemically relate psychotropic drug . Concurrent primary psychiatric neurological diagnosis include organic mental disorder , severe tardive dyskinesia , idiopathic Parkinson 's disease . Existence surgical medical condition , judgement Principal Investigator , might interfere absorption , distribution , metabolism excretion drug likely compromise safety patient . Concurrent use drug know suppress bone marrow function . HIV , HCV , HBsAg positive . Expected change concomitant medication period study . A history epilepsy risk seizure positive urine drug abuse test enrollment . A history alcohol drug dependence Diagnostic statistical manual Mental disorder IV ( DSMIV ) criteria 6 month period immediately prior study entry . A total white blood cell count 4000/ml , absolute neutrophil count 2000/ml Female patient pregnancy Breast feeding intend become pregnant study able follow contraception method . History multiple syncopal episode . Administration study drug last 3 month prior entry study . History significant blood loss due reason past 3 month . Any preexist bleeding disorder .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>